HHS to Launch Campaign Promoting Wearable Devices

June 26, 2025

Reading Time : 2 min

On June 24, 2025, in a hearing before the U.S. House of Representatives Committee on Energy and Commerce, the Secretary of Health and Human Services (HHS), Robert F. Kennedy Jr. revealed that his department plans to soon launch an advertising campaign encouraging Americans to use wearable health devices. The campaign is set to be “one of the biggest advertising campaigns in HHS history.”

As described by Secretary Kennedy, wearables enable individuals to take responsibility over their health and make informed decisions: “People can take control over their own health. . . They can see what food is doing to their glucose levels, their heart rates and a number of other metrics as they eat it. And they can begin to make good judgments about their diet, about their physical activity, about the way that they live their lives,” Secretary Kennedy said.

Secretary Kennedy went on to state that he has observed the positive impact of wearables (like glucose meters) for weight loss and diabetes management. He noted that the wearables were cost-effective—contrasting the expense of a wearable with the cost of a drug such as Ozempic—and said that the department was “exploring ways of making sure that those costs can be paid for.”

“We think that wearables are a key to the MAHA agenda—Making America Healthy Again, and . . . my vision is that every American is wearing a wearable within four years,” added Secretary Kennedy.

This announcement reflects the growing role of digital and wearable health tools in U.S. public health strategy. However, current law draws a significant distinction between wearables used only for “wellness” and wearables that are intended for use in health care decision-making. The latter are generally regulated by the Food and Drug Administration (FDA) as medical devices (or, in some cases, a certain software function available through a wearable is regulated as a medical device). Typically, medical devices need FDA clearance or approval to be covered by federal health programs. Wearable devices also raise data protection and privacy concerns, as they collect large volumes of personal and sensitive health data, which may be shared by third party apps and services. Connectivity and interoperability will also be important considerations, to the extent the objective is for consumers to be able to share this data with their providers. One of the core impediments to leveraging health metric data from wearables has been the lack of consistent approaches to incorporate such data into a patient’s health care records and treatment.

Nevertheless, as the Secretary’s comments before the Energy and Commerce Committee and the House Ways and Means Committee hearing on digital health this week underscore, digital health continues to be an active area of interest for policy-makers that resonates with the MAHA agenda.

Share This Insight

Previous Entries

Eye on FDA

December 22, 2025

On December 18, 2025, the Food and Drug Administration (FDA) released a final guidance entitled “Processes and Practices Applicable to Bioresearch Monitoring Inspections.” The guidance was issued to comply with the Food and Drug Omnibus Reform Act of 2022, which directs FDA to issue guidance describing the processes and practices applicable to inspections of sites and facilities inspected under FDA’s Bioresearch Monitoring (BIMO) inspection program, to the extent that is not covered in already available FDA guides and manuals. The BIMO program was established to assess and monitor the conduct and reporting of FDA-regulated research as well as postmarketing activities through on-site inspections, investigations and Remote Regulatory Assessments.

...

Read More

Eye on FDA

December 15, 2025

On December 5, 2025, FDA announced its Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot, a new voluntary pilot that seeks to accelerate innovation and expand access to digital health devices for people living with chronic conditions. Under TEMPO, FDA will evaluate a new, risk-based enforcement approach that supports digital health devices intended for use to improve patient outcomes in cardio-kidney-metabolic, musculoskeletal and behavioral health conditions. Under the pilot, participating manufacturers may request that the agency exercise enforcement discretion for certain requirements, such as premarket authorization and investigational device requirements, while manufacturers collect and share real-world data demonstrating the device’s performance.

...

Read More

Eye on FDA

November 5, 2025

Last week, FDA released draft guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.” This draft guidance reflects an evolution in FDA’s approach to determining whether a comparative clinical study with efficacy endpoints (a comparative efficacy study or CES) is necessary to support a demonstration of biosimilarity. Specifically, the agency notes that a comparative analytical assessment (CAA) is generally more sensitive when it comes to detecting differences between products than a CES.

...

Read More

Eye on FDA

October 27, 2025

On October 23, 2025, FDA released its final guidance regarding Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. The guidance is the third guidance in a four-part series of FDA guidance focused on patient-focused drug development (PFDD) that describe how stakeholders, such as patients, caregivers, researchers, medical product developers and others can submit patient experience data and other relevant information that can be used for medical product development and regulatory decision making.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.